Newsmakers

Newsmakers

fuboTV (OTC: FBNK) CEO David Gandler Featured by Wedbush Securities Managing Director of Digital Media Equity Research Michael Pachter in Public Company Spotlight

April 29, 2020 admin Comments Off on fuboTV (OTC: FBNK) CEO David Gandler Featured by Wedbush Securities Managing Director of Digital Media Equity Research Michael Pachter in Public Company Spotlight

FaceBank Group, Inc. d/b/a fuboTV [OTCQB:FBNK] CEO David Gandler was featured in a discussion led by Michael Pachter, Managing Director of Digital Media Equity Research at Wedbush Securities, to dive deeper into trends around cord-cutting, […]

Newsmakers

ImagineAR (OTC: IPNFF) Signs Five Year $300,000USD Licensing Agreement with SlapItOn to Provide Augmented Reality for Athletes and Celebrities to Engage Fans

April 29, 2020 admin Comments Off on ImagineAR (OTC: IPNFF) Signs Five Year $300,000USD Licensing Agreement with SlapItOn to Provide Augmented Reality for Athletes and Celebrities to Engage Fans

Contract Revenue is $300,000USD Plus 5 Year Management Program Revenue Fees VANCOUVER and ERIE, PA, April 29, 2020  – Imagine AR Inc. (IP:CSE) (IPNFF:OTCQB) (“ImagineAR” or “Company”) is pleased to announce the signing of a […]

Healthcare

CytoDyn (OTC: CYDY) Announces Vyrologix as Proprietary Name for Leronlimab as a Combination Therapy for Highly Treatment Experienced HIV Patients in the United States

April 27, 2020 admin Comments Off on CytoDyn (OTC: CYDY) Announces Vyrologix as Proprietary Name for Leronlimab as a Combination Therapy for Highly Treatment Experienced HIV Patients in the United States

Company appoints Interim Chief Financial Officer VANCOUVER, Washington, Apr 27, 2020  — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for […]

Healthcare

CytoDyn (OTC: CYDY) Submits Completed Biologics License Application (BLA) to the FDA for Leronlimab as a Combination Therapy for Highly Treatment Experienced HIV Patients

April 27, 2020 admin Comments Off on CytoDyn (OTC: CYDY) Submits Completed Biologics License Application (BLA) to the FDA for Leronlimab as a Combination Therapy for Highly Treatment Experienced HIV Patients

VANCOUVER, Washington, Apr 27, 2020  — During the FDA’s review period, the Company will dedicate all resources to ensure availability of leronlimab for COVID-19 patients; Cancer programs continue with positive results VANCOUVER, Washington, April 27, 2020 […]

Newsmakers

CytoDyn to Hold Conference Call to Provide Updates on Completion of BLA Filing for HIV, Timeline for Potential Approval of Treatment for COVID-19 Patients, and Two Publications, Including The New England Journal of Medicine

April 24, 2020 admin Comments Off on CytoDyn to Hold Conference Call to Provide Updates on Completion of BLA Filing for HIV, Timeline for Potential Approval of Treatment for COVID-19 Patients, and Two Publications, Including The New England Journal of Medicine

VANCOUVER, Washington, Apr 24, 2020  — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that […]

Newsmakers

NexTech AR (OTC: NEXCF) Provides Update on Acquisition of Work From Home (WFH) Virtual Events Webcasting Software Company Jolokia Published: April 23, 2020 at 8:30 a.m. ET

April 23, 2020 admin Comments Off on NexTech AR (OTC: NEXCF) Provides Update on Acquisition of Work From Home (WFH) Virtual Events Webcasting Software Company Jolokia Published: April 23, 2020 at 8:30 a.m. ET

NEW YORK and TORONTO, April 23, Apr 23, 2020 — NexTech AR Solutions (NexTech) (OTCQB: NEXCF) (CSE: NTAR) (FSE: N29), the leader in augmented reality for eCommerce and AR learning applications, is pleased to update […]

Healthcare

CytoDyn (OTC: CYDY) So. California Patients Treated with Leronlimab for COVID-19 under Emergency IND: 4 Patients with Moderate Indications Removed from Oxygen; 3 Patients Discharged from Hospital; 1 Patient Scheduled for Discharge Today; 1 Patient with Severe Indications Discharged, for Total of 5 Patients Discharged

April 13, 2020 admin Comments Off on CytoDyn (OTC: CYDY) So. California Patients Treated with Leronlimab for COVID-19 under Emergency IND: 4 Patients with Moderate Indications Removed from Oxygen; 3 Patients Discharged from Hospital; 1 Patient Scheduled for Discharge Today; 1 Patient with Severe Indications Discharged, for Total of 5 Patients Discharged

VANCOUVER, Washington, Apr 13, 2020  — More than 25 EINDs approved by FDA for leronlimab use in COVID-19 patients Phase 2 trial – As of last week, 12 patients enrolled from 2 sites; 3 more […]

Newsmakers

Floyd Mayweather, fuboTV (OTC: FBNK) Partner in Ground-Breaking Digital Likeness Joint Venture

April 12, 2020 admin Comments Off on Floyd Mayweather, fuboTV (OTC: FBNK) Partner in Ground-Breaking Digital Likeness Joint Venture

fuboTV (OTCQB:FBNK), FaceBank Group, Floyd Mayweather and ONE Entertainment Group, LLC today announced a ground-breaking joint venture to create and manage the world-renowned retired professional boxing champion and promoter’s digital likeness, “Virtual Mayweather.” The partnership […]

Newsmakers

CytoDyn (OTC: CYDY) Collaborating with U.K.’s Department of Health to ProvideEmergency Access to Leronlimab for Severe and Critically Ill COVID-19 Patients

April 7, 2020 admin Comments Off on CytoDyn (OTC: CYDY) Collaborating with U.K.’s Department of Health to ProvideEmergency Access to Leronlimab for Severe and Critically Ill COVID-19 Patients

CEO Nader Pourhassan will appear on FOX Business Network on April 7 at 11:00 am PT to provide an update on the Company’s two COVID-19 clinical trials and 15 patients on EIND VANCOUVER, Washington, Apr […]

Healthcare

CytoDyn (OTC: CYDY) First Two Patients Enrolled in Randomized Phase 2, COVID-19 Trial with Leronlimab; Five More Severely Ill COVID-19 Patients Treated Under Emergency IND and Two Patients Have Already Extubated

April 6, 2020 admin Comments Off on CytoDyn (OTC: CYDY) First Two Patients Enrolled in Randomized Phase 2, COVID-19 Trial with Leronlimab; Five More Severely Ill COVID-19 Patients Treated Under Emergency IND and Two Patients Have Already Extubated

Fifteen (15) severely ill COVID-19 patients have been treated under an EIND; 7-day results from the first four patients are available and are very promising; 7-day results for the first 10 patients will be available […]

Newsmakers

FaceBank Group (OTC: FBNK) and fuboTV Announce Completion of Merger – Combined Company to Be Named fuboTV, Inc.

April 2, 2020 admin Comments Off on FaceBank Group (OTC: FBNK) and fuboTV Announce Completion of Merger – Combined Company to Be Named fuboTV, Inc.

NEW YORK—-fuboTV, Inc., a leading live TV streaming platform, and FaceBank Group, Inc. (OTCQB: FBNK), a leading celebrity and sports focused virtual entertainment company, announced today the closing of their previously announced merger agreement. This […]

Healthcare

CytoDyn (OTC: CYDY) Completes Non-dilutive $15 Million Convertible Note Financing with Conversion Rate at $4.50 Per Share without Warrants

March 31, 2020 admin Comments Off on CytoDyn (OTC: CYDY) Completes Non-dilutive $15 Million Convertible Note Financing with Conversion Rate at $4.50 Per Share without Warrants

VANCOUVER, Washington, Mar 31, 2020  — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that […]

Healthcare

FDA Clears CytoDyn’s (OTC: CYDY) Phase 2 Randomized Trial to Treat Mild-to-Moderately Ill Coronavirus Patients with Leronlimab; Enrollment to Begin Immediately

March 31, 2020 admin Comments Off on FDA Clears CytoDyn’s (OTC: CYDY) Phase 2 Randomized Trial to Treat Mild-to-Moderately Ill Coronavirus Patients with Leronlimab; Enrollment to Begin Immediately

VANCOUVER, Washington, March 31, 2020 — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the […]